logo
Northwell Health Opens Center for Bioelectronic Medicine

Northwell Health Opens Center for Bioelectronic Medicine

Business Wire13-05-2025

NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--After decades of pioneering bioelectronic medicine research, Northwell Health today announced the opening of its clinical Center for Bioelectronic Medicine. Those interested in participating in bioelectronic medicine clinical trials, including studies evaluating vagus nerve stimulation, can do so through the new Center. As bioelectronic medicine devices are approved for use, they will be offered to patients at the Center.
The first Center is located at 350 Community Drive in Manhasset, NY. The facility features a waiting area, patient rooms and a clinical space for research nurses, doctors and clinical trial coordinators to consult with patients and participants. Northwell intends to relocate and expand the Manhasset location within the next few years. Planning is underway for a second center located in Manhattan, NY.
'Northwell Health prides itself on offering patients innovative treatment. Bioelectronic medicine has shown benefit to patients in clinical trials, and with the development and expansion of the field, we have an opportunity to offer this cutting-edge treatment to our patients,' said Michael J. Dowling, president and CEO of Northwell. 'Northwell's Center for Bioelectronic Medicine is a unique destination where doctors, scientists and patients will explore and potentially benefit from today's medical advancements.'
The scientific foundation of bioelectronic medicine stems from research conducted by Kevin J. Tracey, MD, president and CEO of The Feinstein Institutes for Medical Research, Northwell's home of medical research, and author of the new book The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing Reflexes – available today. For nearly four decades, Dr. Tracey and collaborators published their discoveries about a link between the brain, immune system, and inflammation and whether or not their connection could be modulated through technology and electrical signals, like vagus nerve stimulation. Today, bioelectronic medicine clinical trials are conducted at Northwell and around the world. In 2023, Northwell was a site for the SetPoint Medical RESET-RA study, which evaluated a novel treatment option for rheumatoid arthritis (RA) using neuroimmune modulation, a therapy that uses electrical stimulation to modulate functions of the immune system.
Dawn Steiner, one of the RESET-RA trial participants, has firsthand experience with the debilitating effects of RA. For more than a decade, the 58-year-old speech and language pathologist from Massapequa, NY, felt excruciating pain that often left her bedridden. An avid Mets fan and concertgoer, Dawn found herself unable to enjoy the things she loved – or even conduct everyday tasks, like brushing her teeth or tying her shoes – because of her RA flare-ups or her medication's side effects. Over the years, she tried more than eight biological RA medications that often didn't relieve her symptoms and made her feel troubling side effects. After seeing family and friends benefit from enrolling in clinical trials for other conditions, Dawn enrolled in the SetPoint Medical trial and today many of her symptoms are relieved.
'A year after receiving this therapy, I feel as good as I did before my RA diagnosis – like a different person. I feel better, and I'm able to just feel healthy and do all the things that make me happy without those awful, awful medications,' Steiner said. 'To the researchers, thank you! I'm so glad you looked into a different type of technology. From my perspective, this is the future of rheumatoid arthritis treatment.'
The new Center will aim to connect participants like Dawn to bioelectronic medicine clinical trials. Current bioelectronic medicine trials underway at Northwell include treatments for pediatric inflammatory bowel disease, methods to stop excessive bleeding, treatments for post-traumatic stress disorders and brain implant applications to reverse paralysis.
'There is optimism that bioelectronic medicine could replace some drugs that have serious side effects and associated costs, and I am interested in continuing research in this field to better understand the language of the nervous system and see if we can use that knowledge to help the body heal itself,' said Dr. Tracey, Karches Family Distinguished Chair in Medical Research at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. 'Clinical trial participants are my heroes – their courage and commitment send ripples of change throughout medicine, bringing us closer to a future where we can treat diseases in safer, more effective, and personalized ways.'
At the Feinstein Institutes, medical researchers use modern technology to develop novel device-based therapies to treat disease and injury. Engineers, computer scientists, immunologists, neuroscientists, and clinicians develop cutting-edge medicine, including neuroimmune modulation, miniature implants for stimulating and recording the vagus nerve, noninvasive ultrasound neuromodulation to suppress inflammation, and novel brain-computer interfaces to overcome injuries of the nervous system.
In the early 2000s, Dr. Tracey and his colleagues discovered that the brain regulates the production of inflammatory proteins, a key aspect of the body's immune response. This brain-body-immune connection was termed the 'inflammatory reflex.' Despite the revelation more than two decades ago, a recent national survey conducted by Ipsos on behalf of the Feinstein Institutes suggests that many Americans are unaware of this connection between the brain and the body. According to the survey, nearly two-thirds of Americans (64%) don't believe or don't know that the brain controls inflammation. Uncontrolled inflammation can contribute to diseases like RA, Crohn's disease, and inflammatory bowel disease. Dr. Tracey's research led to the founding of SetPoint Medical in 2007; where he currently serves as an advisor. Dr. Tracey's book, The Great Nerve, explores the groundbreaking discovery of how stimulating the vagus nerve can treat chronic illnesses and improve overall health, offering both scientific explanations and real-life patient stories.
For more information about bioelectronic medicine, click here. If you are interested in learning more about the center and current bioelectronic clinical trials offered at Northwell Health, click here or call 1-227-BIO-INST (246-4678).
For download able photos and videos of Dawn, Dr. Tracey, the Center for Bioelectronic Medicine and others, click here.
About Northwell Health
Northwell is the largest not-for-profit health system in the Northeast, serving residents of New York and Connecticut with 28 hospitals, more than 1,000 outpatient facilities, 22,000 nurses and over 20,000 physicians. Northwell cares for more than three million people annually in the New York metro area, including Long Island, the Hudson Valley, western Connecticut and beyond, thanks to philanthropic support from our communities. Northwell is New York State's largest private employer with over 104,000 employees – including members of Northwell Health Physician Partners and Nuance Health Medical Practices – who are working to change health care for the better. Northwell is making breakthroughs in medicine at the Feinstein Institutes for Medical Research. Northwell is training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, X, Instagram and LinkedIn.
About the Feinstein Institutes:
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo

time18 hours ago

  • Yahoo

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo

time19 hours ago

  • Yahoo

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology

Yahoo

time20 hours ago

  • Yahoo

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology

IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine. With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty. This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. BANGKOK, June 06, 2025--(BUSINESS WIRE)--IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. As part of the congress, IBSA Derma will host a scientific symposium titled "The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line" scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead the session, focusing on the evolving approaches in regenerative aesthetic medicine, with particular attention to the clinical impact of hybrid cooperative complexes (HCCs) of hyaluronic acid and their role in tissue regeneration across different anatomical layers affected by aging. HCCs represent a new frontier in hyaluronic acid-based product formulation, made possible through NAHYCO® Technology, IBSA's patented thermal process that celebrates its 10th anniversary this year. This technological breakthrough is the foundation of the Profhilo® line and continues to be a milestone of IBSA Derma's innovation pathway. The Company's presence at IMCAS Asia is part of a broader strategic plan for expansion across the APAC region, an increasingly dynamic and high-potential market. In this context, IBSA Derma strengthened its regional presence last year with the opening of its regional hub in Singapore and the launch of a dedicated platform for Asian Key Opinion Leaders to share their clinical insights and expertise. "The strong growth we are experiencing in the APAC region stems from our solid collaboration with local distributors, which enable us to better understand the specific dynamics and cultural nuances of each market" – says Loy Derris, Business Development Director Dermoaesthetic Division North Asia. "Over the past 18 months, we have achieved remarkable results in countries such as Indonesia, Vietnam, Japan, and India, and we have recently entered the Thai market with great momentum. Looking ahead we are also looking enthusiastically toward promising new markets like Taiwan" – declares Magallon Riza Marie, Senior Strategic Marketing and Operational Lead Dermoaesthetic APAC Region. "Being at IMCAS Asia for the second year in a row is a valuable opportunity to strengthen our dialogue with physicians in the APAC Region and promote our concept of authentic beauty that embraces a holistic and overall wellness-oriented approach" – states Elisa Brozzelli, Brand Activation Manager Dermoaesthetic Division. IBSA Derma will also be present at Booth 8 - Level 2, where visitors can learn more about the latest solutions and innovations in aesthetic medicine. About IBSA IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA will celebrate the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA's growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. About IBSA Derma IBSA has used its experience and expertise in the pharmaceutical field to branch out and develop medical devices for aesthetic medicine based on hyaluronic acid, thus creating a dedicated division: IBSA Derma. Through scientific expertise, continuous research, technological development and a modern production process, IBSA has become one of the leading pharmaceutical companies to produce hyaluronic acid for aesthetic medicine applications. IBSA Derma distinguishes itself in this vast market because it controls the entire product lifecycle, from the biofermentation production of the raw material to the ready-to-use final product in prefilled syringes. View source version on Contacts For further information: Giulia Drei, PR and Communication SpecialistDermoaesthetic Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store